^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

A-1592668

i
Other names: A-1592668
Associations
Trials
Company:
AbbVie
Drug class:
CDK9 inhibitor
Associations
Trials
3years
A Novel Aggressive NK Cell Leukemia Cell Line and Mouse Model for Evaluation of Therapeutic Candidates (ASH 2021)
Single agent of venetoclax, BCL-xl inhibitor (A-1331852), and CDK9 inhibitor (A-1592668), at range of 1 – 1000 nM, had no detectable (BCL-2), mild (BCL-xL), and strong (CDK9) killing activities against CCANKL cells...Administration of either anti-CD6 IgG or CD6-ADC (4 mg/kg) on the same day as inoculation of CCANKL cells in NSG mice blocked engraftment of these malignant cells in NSG mice... A novel aggressive NK cell leukemia cell line and a NSG mouse model were established. The in vitro data support further investigation of the expression features of BCL-2 family proteins in ANKL cases and in vivo evaluation for the efficiency of anti-apoptotic protein inhibitors in this aggressive disease. Further studies targeting CD6 in ANKL is warranted.
Preclinical • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • IL2 (Interleukin 2) • CD2 (CD2 Molecule)
|
BCL2 expression • BCL2 positive • MCL1 expression
|
Venclexta (venetoclax) • A-1331852 • A-1592668 • CD6-ADC